The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review
- PMID: 23858045
- DOI: 10.3899/jrheum.121380
The 15% rule in scleroderma: the frequency of severe organ complications in systemic sclerosis. A systematic review
Abstract
Objective: The prevalence of organ complications in scleroderma (systemic sclerosis; SSc) varies by definition used. This study was done to determine the frequency of several features of SSc.
Methods: A search of Medline-Ovid/Embase, PubMed, and Scopus databases from 1980 to November 30, 2011, was conducted to identify relevant articles with at least 50 patients with SSc extracting prevalence of each organ complication. Study quality was assessed using the STROBE (Strengthening The Reporting of OBservational studies in Epidemiology) checklist. Pooled prevalence was calculated using the random effects method. Heterogeneity was quantified using I(2).
Results: A total of 5916 articles were identified (913 from Medline-Ovid/Embase, 1009 from PubMed, and 3994 from Scopus); 5665 were excluded, leaving 251 articles for full-text review, with 69 included. Where available, frequencies were also included from the Canadian Scleroderma Research Group. Many severe complications in SSc occur about 15% of the time, including cardiac involvement (15%, 95% CI 6-24), diastolic dysfunction (16%, 95% CI 14-17), estimated pulmonary artery pressure > 40 mm Hg (18%, 95% CI 14-21), pulmonary arterial hypertension by right heart catheterization (15%, 95% CI 12-17), forced vital capacity (FVC) < 70% predicted (15%, 95% CI 12-17), FVC < 80% predicted (17%, 95% CI 12-21), myositis (13%, 95% CI 10-17), inflammatory arthritis (12%, 95% CI 9-16), Sjögren overlap (13%, 95% CI 10-16), and digital ulcers (DU; 15%, 95% CI 10-20); and 15% of DU have complications (amputations 12%, 95% CI 8-16, and hospitalizations 13%, 95% CI 6-21). Scleroderma renal crisis is uncommon but occurs in almost 15% (12%, 95% CI 5-19) of cases of disseminated cutaneous SSc. There is no 15% rule within skin and gastrointestinal tract for SSc.
Conclusion: The "15%" rule for frequency of significant organ involvement in SSc is helpful.
Keywords: DIGITAL ULCER; MYOPATHY; PULMONARY ARTERY HYPERTENSION; PULMONARY FIBROSIS; RENAL CRISIS; SCLERODERMA.
Similar articles
-
Cyclophosphamide for connective tissue disease-associated interstitial lung disease.Cochrane Database Syst Rev. 2018 Jan 3;1(1):CD010908. doi: 10.1002/14651858.CD010908.pub2. Cochrane Database Syst Rev. 2018. PMID: 29297205 Free PMC article.
-
Stem cell transplantation for systemic sclerosis.Cochrane Database Syst Rev. 2022 Jul 29;7(7):CD011819. doi: 10.1002/14651858.CD011819.pub2. Cochrane Database Syst Rev. 2022. PMID: 35904231 Free PMC article.
-
Dynamics of interstitial lung disease following immunosuppressive treatment differ between antisynthetase syndrome and systemic sclerosis.Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251336896. doi: 10.1177/17534666251336896. Epub 2025 May 8. Ther Adv Respir Dis. 2025. PMID: 40337907 Free PMC article.
-
Prevalence and predictors of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review and meta-analysis.Clin Rheumatol. 2021 Aug;40(8):3039-3051. doi: 10.1007/s10067-020-05549-8. Epub 2021 Jan 11. Clin Rheumatol. 2021. PMID: 33426631
-
Secondary cryofibrinogenemia is related to more severe microangiopathic involvement in systemic sclerosis: results from a retrospective observational study.Clin Rheumatol. 2025 Mar;44(3):1173-1185. doi: 10.1007/s10067-025-07324-z. Epub 2025 Jan 20. Clin Rheumatol. 2025. PMID: 39832067 Free PMC article.
Cited by
-
Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention.Open Access Rheumatol. 2019 Dec 9;11:283-307. doi: 10.2147/OARRR.S226695. eCollection 2019. Open Access Rheumatol. 2019. PMID: 31849543 Free PMC article.
-
Prevalence of other connective tissue diseases in idiopathic inflammatory myopathies.Rheumatol Int. 2019 Oct;39(10):1777-1781. doi: 10.1007/s00296-019-04411-8. Epub 2019 Aug 5. Rheumatol Int. 2019. PMID: 31385080
-
Current Approaches to the Treatment of Systemic-Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH).Curr Rheumatol Rep. 2016 Feb;18(2):10. doi: 10.1007/s11926-015-0560-x. Curr Rheumatol Rep. 2016. PMID: 26841964 Review.
-
Points to consider in renal involvement in systemic sclerosis.Rheumatology (Oxford). 2017 Sep 1;56(suppl_5):v49-v52. doi: 10.1093/rheumatology/kex201. Rheumatology (Oxford). 2017. PMID: 28992172 Free PMC article. Review.
-
Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate).Ann Rheum Dis. 2018 Feb;77(2):212-220. doi: 10.1136/annrheumdis-2017-211682. Epub 2017 Oct 24. Ann Rheum Dis. 2018. PMID: 29066464 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical